Spero Therapeutics (SPRO) Debt to Equity (2016 - 2026)
Spero Therapeutics posted quarterly Debt to Equity of $0.0 for Q1 2026, up 11.5% on a QoQ basis from $0.0 in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Debt to Equity data on file, last reported at $0.0 in Q1 2026.
- For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to $0.0; the trailing twelve-month figure through Mar 2026 stood at $0.0 (changed N/A YoY), and the FY2025 full-year result was $0.0, changed N/A from the prior year.
- Debt to Equity for Q1 2026 stood at $0.0, up from $0.0 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.02 in Q1 2022 and bottomed at $0.0 in Q3 2024.
- The 5-year median for Debt to Equity is $0.0 (2023), against an average of $0.0.
- The widest annual swing landed in 2022, when Debt to Equity soared 1171.64%; it then slumped 92.71% in 2023.
- A 5-year view of Debt to Equity shows it stood at $0.0 in 2022, then tumbled by 35.62% to $0.0 in 2023, then tumbled by 75.62% to $0.0 in 2024, then soared by 676.93% to $0.0 in 2025, then rose by 11.5% to $0.0 in 2026.
- The last three Debt to Equity figures came in at $0.0 (Q1 2026), $0.0 (Q4 2025), and $0.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.01 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.02 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2020 | 0.00 |
| Sep 30, 2020 | 0.00 |
| Jun 30, 2020 | 0.00 |
| Mar 31, 2020 | 0.00 |
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 0.01 |
| Jun 30, 2019 | 0.00 |
| Mar 31, 2019 | 0.00 |
| Dec 31, 2018 | 0.00 |
| Sep 30, 2018 | 0.00 |
| Jun 30, 2018 | 0.00 |
| Mar 31, 2018 | 0.00 |
| Dec 31, 2017 | 0.00 |
| Sep 30, 2017 | 0.00 |
| Dec 31, 2016 | -0.05 |